Transcriptomics

Dataset Information

0

Comparison of gene expression between natural ligand treatment and agonistic antibody treatment in a CD30+ cell line


ABSTRACT: CD30 receptor (TNFRSF8) is highly expressed in some types of lymphoma. CD30 is successfully used as a target for antibody-drug conjugate to treat CD30+ lymphoma. The agonistic activity of the anti-CD30 antibody likely contributes to tumor cell killing. However, not all antibodies exhibit agonistic activity. We found that potent agonistic antibodies recognize the N-terminus epitope cluster that is distantly located from the ligand binding site of CD30. This study compared gene expression profiles between CD30 natural ligand and agonistic antibody T104 treatment in a CD30+ ALCL Karpas 299 cell line.

ORGANISM(S): Homo sapiens

PROVIDER: GSE59174 | GEO | 2025/08/10

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2025-08-10 | GSE67794 | GEO
2009-10-10 | GSE13261 | GEO
2010-04-08 | E-GEOD-13261 | biostudies-arrayexpress
2019-01-25 | GSE109620 | GEO
2025-06-12 | GSE272007 | GEO
2023-03-24 | GSE228113 | GEO
2023-03-22 | GSE227653 | GEO
2018-06-13 | GSE83441 | GEO
| PRJNA254536 | ENA
2020-05-28 | GSE151301 | GEO